AUS
NZ
UK
CA
USA
IND
Highlights
- Singapore’s Health Sciences Authority grants approval for Striate+
- Global sales growth continues with strong adoption rates
- Expansion efforts underway with entry into new international markets
Orthocell (ASX:OCC) has secured regulatory approval from Singapore’s Health Sciences Authority (HSA) for its advanced dental guided bone regeneration product, Striate+. This latest approval strengthens the company’s global presence, complementing existing clearances in the United States, Europe, the United Kingdom, Australia, New Zealand, and Canada.
Expanding Market Reach
With this approval, Orthocell can now introduce Striate+ to the Singaporean market, a key gateway for expansion into the broader Asia-Pacific region. The product has been gaining traction in major international markets, reflecting increasing demand from dental professionals.
Striate+ has demonstrated a 98.6% success rate in post-market clinical studies, driving strong adoption among dental surgeons. The global market opportunity for this technology is valued at over AU$1 billion, positioning Orthocell for significant growth.
Strong Financial Position
Orthocell maintains a solid financial standing, with approximately AU$33 million in cash reserves. This financial stability enables the company to further expand its commercial operations and strengthen its footprint in existing and emerging markets. The approval in Singapore enhances revenue potential, as it allows the company’s distribution partner to accelerate global expansion efforts.
Strategic Partnerships and Future Growth
To support this expansion, Orthocell is collaborating with BioHorizons, a leading dental implant and tissue regeneration company, to drive market penetration. Plans are already in motion to enter additional key markets, with regulatory approval in Brazil expected within the next three to six months.
Paul Anderson, CEO and Managing Director of Orthocell, highlighted the significance of this approval, emphasizing that it validates the company’s high-quality products, manufacturing excellence, and rigorous quality systems. The milestone also reinforces Orthocell’s commitment to providing advanced solutions for dental professionals worldwide.
Positive Market Outlook
With strong clinical results, expanding regulatory approvals, and a growing global presence, Orthocell is positioned for continued momentum. The company’s focus on expanding into high-growth markets aligns with increasing global demand for innovative dental regeneration solutions. As new approvals pave the way for wider adoption, Orthocell remains on track for sustained growth in the competitive medical technology sector.
